Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELYM Eliem Therapeutics	$1.21 -1.6%	$1.26	$2.35 ▼ $11.55	$36M	-0.39	486,688 shs	189,507 shs
LRMR Larimar Therapeutics	$2.42 -6.6%	$2.32	$1.61 ▼ $11.20	$165.83M	0.79	827,819 shs	3.06 million shs
NBTX Nanobiotix	$4.45 -0.5%	$3.92	$2.76 ▼ $6.00	$210.68M	0.36	15,697 shs	1,877 shs
PBYI Puma Biotechnology	$3.35 +5.0%	$3.24	$2.23 ▼ $4.13	$158.57M	1.29	443,266 shs	323,078 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELYM Eliem Therapeutics	0.00%	-3.97%	+2.54%	-8.33%	-85.40%
LRMR Larimar Therapeutics	-6.56%	-16.26%	+29.41%	+4.76%	-70.23%
NBTX Nanobiotix	-0.47%	-10.75%	+17.11%	+23.07%	+6.95%
PBYI Puma Biotechnology	+5.02%	-2.90%	+3.72%	+3.08%	+12.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	2.7485 of 5 stars	3.6	3.0	0.0	0.0	2.4	1.7	0.6
NBTX Nanobiotix	2.1794 of 5 stars	3.3	5.0	0.0	0.0	1.1	0.0	0.6
PBYI Puma Biotechnology	4.0789 of 5 stars	3.5	2.0	0.0	0.0	1.9	4.2	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
LRMR Larimar Therapeutics	3.11	Buy	$19.67	712.67% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	79.82% Upside
PBYI Puma Biotechnology	3.00	Buy	$7.00	108.96% Upside

Current Analyst Ratings Breakdown

Latest ELYM, LRMR, NBTX, and PBYI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/4/2025	NBTX Nanobiotix	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00
3/25/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/25/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00 ➝ $26.00
3/25/2025	LRMR Larimar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $16.00
3/25/2025	LRMR Larimar Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$13.00 ➝ $10.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A
NBTX Nanobiotix	-$11.61M	-18.06	N/A	N/A	($1.51) per share	-2.95
PBYI Puma Biotechnology	$230.50M	0.72	$0.89 per share	3.75	$1.88 per share	1.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/6/2025 (Estimated)
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	$30.28M	$0.77	4.35	8.82	N/A	16.37%	49.35%	18.25%	7/30/2025 (Estimated)

Latest ELYM, LRMR, NBTX, and PBYI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/30/2025	Q1 2025	LRMR Larimar Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A
3/24/2025	Q4 2024	LRMR Larimar Therapeutics	-$0.29	-$0.45	-$0.16	-$0.45	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELYM Eliem Therapeutics	N/A	60.41	60.41
LRMR Larimar Therapeutics	N/A	7.48	7.48
NBTX Nanobiotix	N/A	1.04	1.04
PBYI Puma Biotechnology	0.11	1.53	1.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELYM Eliem Therapeutics	69.76%
LRMR Larimar Therapeutics	91.92%
NBTX Nanobiotix	38.81%
PBYI Puma Biotechnology	61.29%

Insider Ownership

Company	Insider Ownership
ELYM Eliem Therapeutics	4.70%
LRMR Larimar Therapeutics	4.50%
NBTX Nanobiotix	3.45%
PBYI Puma Biotechnology	23.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
LRMR Larimar Therapeutics	30	64.03 million	61.15 million	Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable
PBYI Puma Biotechnology	200	49.63 million	38.07 million	Optionable

ELYM, LRMR, NBTX, and PBYI Headlines

Recent News About These Companies